Biopharma Co. Says Investor Suit Tries To Go Around Board
By Rose Krebs ( August 1, 2019, 8:44 PM EDT) -- Biopharmaceutical company Ultragenyx Pharmaceutical Inc. told a Delaware vice chancellor on Thursday that a derivative stockholder suit claiming company directors are paid excessive salaries is a procedurally improper go-around filed after the investor made a litigation demand on the board that was rejected....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.